Patricia Inácio, PhD, science writer —

People with hereditary angioedema (HAE) typically experience a markedly delayed diagnosis — from three to 26 years following the onset of symptoms — that results in a greater disease burden for patients, with growing HAE-related expenses from hospitalizations, medications, potentially unnecessary surgeries, and a plethora of doctor visits, according…

Children in Egypt with hereditary angioedema (HAE) wait an average of three years to be diagnosed, according to a small study. Delayed diagnosis was common despite more than half the children in the study having a family history of the disease. About half of the 18 patients in the study…

Otsuka Pharmaceutical has obtained exclusive rights to commercialize donidalorsen for hereditary angioedema (HAE) in the Asia-Pacific region. The deal is an extension of a previous license agreement that granted Otsuka the rights to commercialize the therapy in Europe. Ionis Pharmaceuticals, the therapy’s original developer, retains…

Deucrictibant, an experimental treatment for hereditary angioedema (HAE), now has shown promising efficacy as an on-demand and prophylactic, or preventive, treatment in three patients with acquired angioedema. The findings, from a small clinical trial, suggest that “deucrictibant has the potential to effectively and safely treat and prevent…

Orladeyo (berotralstat), an oral therapy designed to prevent swelling attacks in adults and adolescents with hereditary angioedema (HAE), has now been approved in Mexico. The approval by the Mexican Federal Commission for Protection against Health Risks (COFEPRIS) covers the use of Orladeyo as a prophylactic, or preventive, treatment for HAE…

Hereditary angioedema (HAE) is marked by frequent attacks and high disease burden in Canadian patients, who waited a median of 10 years for a diagnosis after the onset of their symptoms, a recent survey shows. This reality “indicates an urgent need for increased awareness and education on HAE among…

A dozen new mutations in the SERPING1 gene were identified in Slovakia as the cause of hereditary angioedema (HAE) due to C1-inhibitor deficiency or dysfunction — known as C1-INH-HAE — according to a new study based on a complex analysis. That genetic analysis also suggested that the prevalence of…

The use of vaccines against SARS-CoV-2, the virus that causes COVID-19, was not linked to an increased risk of disease worsening in people with hereditary angioedema (HAE), according to a small, single-center study from Turkey. The study also found that the viral infection was not always associated with disease worsening…

Treatment with tranexamic acid was safe and not linked to a higher risk of worse outcomes in people who developed angioedema after being on angiotensin-converting enzyme inhibitors (ACEIs), a type of blood pressure-lowering medication, a study finds. While initial findings suggested a link between tranexamic acid and greater rates…

Preventive treatment with Takhzyro (lanadelumab) reduced swelling attack frequency and improved quality of life in Japanese patients with hereditary angioedema (HAE), a small real-world study shows. The study, “Effect of lanadelumab on attack frequency and QoL in Japanese patients with hereditary angioedema: Report of five…